PPD Launches IPO
Drug development contract services company PPD announces initial public offering.
On Jan. 27. 2020, contract service provider PPD, Inc. announced the launch of an initial public offering (IPO), potentially worth $1.6 billion; the company said it intends to use the net proceeds from the IPO to cover debt and for general corporate purposes.
In a press statement, the company said it plans to issue 60 million shares of its common stock with the initial stock price expected to be between $24–$27 per share, the company reported.
The company has applied with the Securities and Exchange Commission to have its common stock approved for listing on The Nasdaq Global Select Market under the symbol “PPD.”
Source: PPD Inc.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
